Navigation Links
Nasdaq Hearings Panel Grants TeamStaff's Request for Continued Listing Subject to a Reverse Stock Split
Date:3/12/2008

amStaff Rx and TeamStaff Government Solutions. TeamStaff Rx is a leading provider of travel nursing and travel allied healthcare professionals. TeamStaff Rx operates throughout the U.S. and specializes in the supply of travel allied medical employees and travel nurses typically placed on 13 week assignments. TeamStaff Government Solutions specializes in providing medical, logistics and office administration/technical professionals through nationwide Federal Supply Schedule contracts with both the United States General Services Administration and the United States Department of Veterans Affairs. For more information, visit the TeamStaff web site at http://www.teamstaff.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

This press release contains "forward-looking statements" as defined by the Federal Securities Laws. Statements in this press release regarding TeamStaff, Inc.'s business, which are not historical facts are "forward-looking statements" that involve risks and uncertainties. TeamStaff's actual results could differ materially from those described in such forward-looking statements as a result of certain risk factors and uncertainties, including but not limited to: our ability to recruit and retain qualified temporary and permanent healthcare professionals and administrative staff upon acceptable terms; our ability to enter into contracts with hospitals, healthcare facility clients, affiliated healthcare networks, physician practice groups, government agencies and other customers on terms acceptable to us and to secure orders related to those contracts; changes in the timing of customer orders for placement of temporary and permanent healthcare professionals and administrative staff; the overall level of demand for our services; our ability to successfully implement our strategic growth, acquisition and integration strategies; the effect of existing or f
'/>"/>

SOURCE TeamStaff, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
2. IDM Pharma Announces Compliance With NASDAQ Minimum Bid Price Requirements
3. Amarin Regains Compliance With Nasdaq Listing Requirements
4. IDM Pharma Receives Notification from NASDAQ Relating to Minimum Bid Price
5. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
6. TeamStaff Receives Nasdaq Determination Letter
7. QMed, Inc. Receives NASDAQ Letter
8. Chindex International, Inc. Announces Transfer to NASDAQ Global Market
9. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
10. Elbit Imaging Ltd. Selected for Listing on Nasdaq Global Select Market
11. HEI, Inc. Initiates Delisting and Deregistration of Its Shares on NASDAQ
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Want to Stop Cancer 3F You Can Experts Say 47763 1Want to Stop Cancer 3F You Can Experts Say 47763 2Want to Stop Cancer 3F You Can Experts Say 47763 3New Ad Campaign Asks D C Commuters Whos Hogging Our Antibiotics 3F 47760 1New Ad Campaign Asks D C Commuters Whos Hogging Our Antibiotics 3F 47760 2Lilly Resubmits Cymbalta 28R 29 Supplemental New Drug Application for Chronic Pain to U S Food and Drug Administration 47758 1Lilly Resubmits Cymbalta 28R 29 Supplemental New Drug Application for Chronic Pain to U S Food and Drug Administration 47758 2Lilly Resubmits Cymbalta 28R 29 Supplemental New Drug Application for Chronic Pain to U S Food and Drug Administration 47758 3Lilly Resubmits Cymbalta 28R 29 Supplemental New Drug Application for Chronic Pain to U S Food and Drug Administration 47758 4